Aastrom Biosciences Says First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel-T

Aastrom Biosciences, Inc. (Nasdaq: ASTM ), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that the first patients have been enrolled in the ixCELL-DCM clinical trial. This Phase 2b study is currently underway in the United States to assess the efficacy and safety of